Literature DB >> 17013822

Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.

Rafael Ariza-Ariza1, Blanca Hernández-Cruz, Loreto Carmona, Maria Dolores Ruiz-Montesinos, Javier Ballina, Federico Navarro-Sarabia.   

Abstract

OBJECTIVE: To compare the utility values and quality-adjusted life years (QALYs) obtained by the Time Trade-Off instrument (TTO) and the EuroQol-5D (EQ-5D) in patients with rheumatoid arthritis (RA); to analyze the association between utility values and Disease Activity Score 28 (DAS28) and Health Assessment Questionnaire (HAQ).
METHODS: We conducted a longitudinal, prospective, 1-year study of RA patients selected randomly from 10 rheumatology clinics. TTO and EQ-5D were administered at 4 scheduled visits.
RESULTS: The study sample comprised 300 RA patients (82% women, mean age 59 years, mean disease duration 10.3 years). A total of 260 patients completed both the TTO and the EQ-5D at baseline, and the mean +/- SD TTO scores were significantly higher than the EQ-5D scores (0.81 +/- 0.22 versus 0.53 +/- 0.35, P < 0.0001). The intraclass correlation coefficient (ICC) for the utility methods was 0.19. Data about changes in both TTO and EQ-5D scores during the study year were available in 163 patients. These changes tended to be larger in the TTO scores than the EQ-5D scores (mean +/- SD 0.05 +/- 0.25 versus -0.005 +/- 0.35, P = 0.054). The ICC for the mean changes in the utility scores was 0.24. Patients obtained a mean +/- SD of 0.04 +/- 0.20 QALYs based on TTO scores and 0.004 +/- 0.27 based on EQ-5D scores (P = 0.12). At baseline, the EQ-5D scores were highly correlated with the HAQ (r = -0.74) and moderately correlated with the DAS28 (r = -0.47), whereas the TTO correlated poorly with both the HAQ and DAS28. Correlation between the mean change in the EQ-5D and in the HAQ was moderate (r = -0.55).
CONCLUSION: TTO and EQ-5D do not yield the same utility values. The results suggest that the EQ-5D is more representative of RA status than the TTO, a valuable conclusion when addressing economic evaluations in RA.

Entities:  

Mesh:

Year:  2006        PMID: 17013822     DOI: 10.1002/art.22226

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  18 in total

1.  How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?

Authors:  Annelies Boonen; Désirée van der Heijde; Robert Landewé; Astrid van Tubergen; Herman Mielants; Maxime Dougados; Sjef van der Linden
Journal:  Ann Rheum Dis       Date:  2007-01-09       Impact factor: 19.103

2.  Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis.

Authors:  Dinesh Khanna; Daniel E Furst; Weng Kee Wong; Joel Tsevat; Philip J Clements; Grace S Park; Arnold E Postlethwaite; Mansoor Ahmed; Shaari Ginsburg; Ron D Hays
Journal:  Qual Life Res       Date:  2007-04-03       Impact factor: 4.147

3.  Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.

Authors:  Anthony Russell; Ariel Beresniak; Louis Bessette; Boulos Haraoui; Proton Rahman; Carter Thorne; Ross Maclean; Danielle Dupont
Journal:  Clin Rheumatol       Date:  2008-12-17       Impact factor: 2.980

Review 4.  A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation.

Authors:  Tom W C Lung; Alison J Hayes; Andrew Hayen; Andrew Farmer; Philip M Clarke
Journal:  Qual Life Res       Date:  2011-04-07       Impact factor: 4.147

5.  Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project.

Authors:  Ariel Beresniak; Antonieta Medina-Lara; Jean Paul Auray; Alain De Wever; Jean-Claude Praet; Rosanna Tarricone; Aleksandra Torbica; Danielle Dupont; Michel Lamure; Gerard Duru
Journal:  Pharmacoeconomics       Date:  2015-01       Impact factor: 4.981

6.  Mapping between HAQ-DI and EQ-5D-5L in a Chinese patient population.

Authors:  Thomas Patton; Hao Hu; Luan Luan; Keqin Yang; Shu-Chuen Li
Journal:  Qual Life Res       Date:  2018-07-04       Impact factor: 4.147

7.  Total wrist arthroplasty and total wrist arthrodesis in rheumatoid arthritis: a decision analysis from the hand surgeons' perspective.

Authors:  Christi M Cavaliere; Kevin C Chung
Journal:  J Hand Surg Am       Date:  2008-12       Impact factor: 2.230

8.  Population-based utilities for upper extremity functions in the setting of tetraplegia.

Authors:  Ashwin N Ram; Catherine M Curtin; Kevin C Chung
Journal:  J Hand Surg Am       Date:  2009-11       Impact factor: 2.230

9.  Limited correlation between the Health Assessment Questionnaire (HAQ) and EuroQol in rheumatoid arthritis: questionable validity of deriving quality adjusted life years from HAQ.

Authors:  D L Scott; B Khoshaba; E H Choy; G H Kingsley
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

Review 10.  Challenges comparing functional limitations in rheumatoid arthritis and ankylosing spondylitis.

Authors:  G H Louie; J D Reveille; M M Ward
Journal:  Clin Exp Rheumatol       Date:  2009 Jul-Aug       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.